nice88 free 120 download
Palantir Technologies Inc PLTR can thank Elon Musk for its 275% year-to-date gain, according to Jim Cramer . What To Know: Palantir, which rallied nearly 50% over just the past month, maybe the only stock outshining Nvidia Corp NVDA this year, Cramer said Tuesday on CNBC’s “Squawk On The Street.” While both companies have recorded significant gains in 2024 driven by their positioning in the AI space, Cramer credits Musk for driving the recent momentum in Palantir shares. “Palantir is up a lot because I believe Musk is going to turn to them and say, ‘The Defense Department, it’s yours ... get rid of all those people,'” Cramer said. President-elect Donald Trump recently announced plans to nominate Musk and Vivek Ramaswamy to a new Department of Government Efficiency (DOGE) in an effort to curtail government spending. Cramer suggested that DOGE could turn to Palantir for help cutting defense budget spending. He noted that most people don’t realize that some government departments could be cut back substantially. The Tesla CEO could look to Palantir to modernize the Defense Department and reduce reliance on outdated methods of warfare. Palantir is adamant about creating systems that don’t put people in harm’s way, but the Defense Department is stuck in its ways, Cramer said. See Also: Musk, Ramaswamy Should Target TransDigm In Budget Cuts, Short Report Says: ‘Target #1’ For D.O.G.E. Why It Matters : Cramer’s take underscores how influential Musk is expected to be under the incoming Trump administration. It’s worth noting that DOGE wouldn’t actually be able to cut federal spending since it isn’t a real government department, and would need to be created with congressional approval. And Congress authorizes all federal spending, including to the Defense Department. “They like big things. Big expensive programs. Alex [Karp] is not like that,” Cramer said, referring to Palantir’s CEO. “Palantir has the next generation of how we’re going to do cyber warfare and the idea of just hardware, hardware, hardware that is constantly over budget is the kind of thing that I think Musk is really after.” Palantir shares ripped higher at the beginning of November after the company reported strong quarterly results driven by “unrelenting” AI demand. Revenue jumped 30% year-over-year and customer count climbed 39% on continued strength in the U.S. “The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers," Karp said earlier this month. Price Action: Palantir shares were up 0.31% at $64.85 at the time of publication, according to Benzinga Pro . Read Next: Jim Cramer’s Apple Endorsement Sparks ‘Inverse Cramer’ Backlash As Social Media Users Mock His ‘Own It’ Advice Photo: Shutterstock. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.New shoplifting data explains why they’re locking up the toothpaste
Stephen Paul Gale case: How survivors, technology aided long quest for justice
Clearmind Medicine Inc. CMND saw its shares rise on Tuesday after announcing that it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a drug targeting alcohol use disorder (AUD) . This approval marks a significant milestone in the company’s FDA-regulated clinical program, and the trial will be conducted at Yale School of Medicine’s Department of Psychiatry, led by Anahita Bassir Nia , an expert in psychiatry and addiction medicine. The trial will evaluate the safety, tolerability, and efficacy of CMND-100, a proprietary investigational drug designed to reduce alcohol cravings and consumption in individuals with moderate to severe AUD. Adi Zuloff-Shani , CEO of Clearmind Medicine, emphasized the importance of this step, noting that alcohol use is a leading preventable cause of death globally, responsible for 2.6 million deaths annually. Also Read: What’s Going On With NIO Stock On Tuesday? Current treatment options are limited, with low efficacy and patient compliance. Clearmind aims to address this gap with CMND-100, offering a potential solution for treating AUD that could significantly improve patient outcomes. The trial is expected to provide critical data to support the advancement of CMND-100 through its clinical pipeline, offering hope for more effective treatment options for those struggling with alcohol addiction. According to Benzinga Pro , CMND stock has lost over 6% in the past month. Investors can gain exposure to the stock via AdvisorShares Psychedelics ETF PSIL . Price Action: CMND shares are trading higher by 35% to $1.64 at last check Tuesday. Read Action: Bitcoin Flat, Ethereum, Dogecoin Spike Ahead Of Christmas: Analyst Says Decline In BTC Dominance Leaves ‘Room For Altcoins To Pick Up' Photo: Shutterstock This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
New ministers put on their game faces2 Canadians arrested for failed murder plot in Northern California